Trial site
Florida Institute for Clinical Research
Orlando, Florida 32825, United StatesNot linked to an institution yet
- 13running trials
- 2closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 23 trials
- Status
- Active, not recruiting5 trials
- Recruiting5 trials
- Not yet recruiting3 trials
- Completed2 trials
- Lead sponsor
- Amgen7 trials
- Novo Nordisk A/S6 trials
- Boehringer Ingelheim1 trial
- Uniquity One (UNI)1 trial
Running trials
Not yet recruiting
A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity
NCT07919405· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
NCT07931495· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Not yet recruiting
AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
NCT07931573· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight
NCT07871409· Phase 3· Amgen· Source
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
NCT07684144· Phase 3· Amgen· Source
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
NCT07684235· Phase 3· Amgen· Source
Recruiting
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
NCT07575399· Phase 3· Amgen· Source
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858878· Phase 3· Amgen· Source
Active, not recruiting
Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839· Phase 3· Amgen· Source
Active, not recruiting
A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)
NCT06660173· Phase 2· Amgen· Source
Active, not recruiting
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
NCT06496620· Phase 2· Uniquity One (UNI)· Source
Active, not recruiting
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796· Phase 3· Novo Nordisk A/S· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error